(Reuters) - U.S. regulators on Thursday approved BioMarin Pharmaceutical Inc's Palynziq for adults with phenylketonuria, a rare metabolic disorder, sending shares of the biotechnology company up 3 percent after hours.
from Reuters: Health News https://ift.tt/2s4ng4Y
0 comments:
Post a Comment